Prenetics Acquires ACT Genomics First M A Deal since IPO Set to Expand Footprint in Cancer Genomics
- Written by Reporters
- Prenetics will be acquiring a majority stake in ACT Genomics Holdings Company Limited ("ACT") for an upfront consideration consisting of 19.9 million shares of Prenetics common stock and US$20 million cash
- Prenetics expects ACT to contribute revenues of approximately US$25-30 million in 2023
- Position Prenetics solidly within the...

